Meeting
2023 ASCO Annual Meeting
Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.
Authors
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA
Bartosz Chmielowski , Mohammed M. Milhem , Joseph J. Sacco , Tawnya Lynn Bowles , Katy K. Tsai , Gino Kim In , Eva Muñoz-Couselo , Ari M. Vanderwalde , Jason Alan Chesney , Judith Michels , Adel Samson , Georgia Beasley , Dirk Schadendorf , Fade Mahmoud , Michael K.K. Wong , Trisha Michel Wise-Draper , Junhong Zhu , Praveen Bommareddy , Jeannie W. Hou , Mark R. Middleton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03767348
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9509)
DOI
10.1200/JCO.2023.41.16_suppl.9509
Abstract #
9509
Poster Bd #
272
Abstract Disclosures
Similar Posters
First Author: Igor Tsaur
Poster
2023 ASCO Annual Meeting
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).
First Author: Isabella Claudia Glitza
Poster
2023 ASCO Annual Meeting
KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
First Author: Andrea Necchi
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang